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Chronic pain is a multifactorial condition with both physical and psychological symptoms, and it affects 
around 20% of the population in the developed world. In spite of outstanding advances in pain management 
over the past decades, chronic pain remains a significant problem. This article provides a mechanism- and 
evidence-based approach to improve the outcome for pharmacologic management of chronic pain. The usual 
ap p r oach  to  tr eat m ild to m od erate p ain  is to start w ith  a n on o p ioid  an algesic. If this is in adeq uate, an d  if 
there is an element of sleep deprivation, then it is reasonable to add an antidepressant with analgesic qualities. 
If there is a component of neuropathic pain or fibromyalgia, then a trial with one of the gabapentinoids is 
appropriate. If these steps are inadequate, then an opioid analgesic may be added. For moderate to severe pain, 
one would initiate an earlier trial of a long term opioid. Skeletal muscle relaxants and topicals may also be 
appropriate as single agents or in combination. Meanwhile, the steps of pharmacologic treatments for 
neuropathic pain include (1) certain antidepressants (tricyclic antidepressants, serotonin and norepinephrine 
reuptake inhibitors), calcium channel α2-δ ligands (gabapentin and pregabalin) and topical lidocaine, (2) opioid 
analgesics and tramadol (for first-line use in selected clinical circumstances) and (3) certain other 
antidepressant and antiepileptic medications (topical capsaicin, mexiletine, and N-methyl-d-aspartate receptor 
antagonists). It is essential to have a thorough understanding about the different pain mechanisms of chronic 
pain and evidence-based multi-mechanistic treatment. It is also essential to increase the individualization of 
treatment.  (Korean  J  Pain  2010;  23:  99-108)
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INTRODUCTION
    Chronic pain is one of the most prevalent, costly, and 
disabling conditions in both clinical practice and the work-
place, yet it often remains inadequately treated [1]. The 
available guidelines are not universally accepted by those 
involved in pain management, and pain treatment seems 
to be mainly guided by tradition and personal experience 
[2]. Moreover, chronic pain commonly coincides with de-
pression and sleep disturbance, as well as mood and anxi-
ety disorders.
    Neuropathic pain has recently been defined as ''pain 
arising as a direct consequence of a lesion or disease af-
fecting the somatosensory system'' [3]. Treatment of neu-100 Korean J Pain Vol. 23, No. 2, 2010
r opathi c pain is cha ll enging. Com par ed to patien ts with 
n o n n e u r o p a t h i c  c h r o n i c  p a i n ,  p a t i e n t s  w i t h  n e u r o p a t h i c  
pain seem to have higher than average pain scores and 
a lower health-related quality of life (even after adjusting 
for pain scores); they require more medication and they 
report less pain relief with treatment [4,5]. 
    Therefore, it is not so easy to plan eff ective pharma-
cologic therapy for chronic pain. In this article, we will dis-
cuss the major classes of medications as they relate to 
chronic pain management and we offer better treatment 
decisions  and  combination  therapy  by  increasing  phys-
icians' knowledge of the pharmacological options that are 
available to manage different pain mechanisms. 
SPECIFIC  MEDICATIONS
1. Nonopioid analgesics
    Aspirin and other related compounds constitute a 
class of drugs known as nonsteroidal anti-inflammatory 
drugs (NSAIDs). NSAIDs have 3 desirable pharmacological 
e f f e c t s :  a n t i - i n f l a m m a t o r y ,  a n a l g e s i c ,  a n d  a n t i p y r e t i c  
effects. All NSAIDs and COX-2 agents appear to be equal-
ly effective in the treatment of pain disorders [6]. While 
gastrointestinal (GI) adverse effects have traditionally been 
considered the most common and worrisome complication 
of NSAIDs, the cardiovascular risk has gained increasing 
attention,  and  this  has  prompted  the  American  Heart 
Association to recommend acetaminophen, nonacetylated 
salicylates and even short-term opioids instead of NSAIDs 
and particularly COX-2 agents in patients with coronary 
artery disease [7]. Acetaminophen has analgesic and anti-
pyretic effects similar to NSAIDs, but it lacks a specific 
anti-inflammatory  effect.  Acetaminophen  is  a  slightly 
weaker analgesic than NSAIDs [8-10], but it is a reason-
able first-line option because of its more favorable safety 
profile and low cost. However, acetaminophen is associated 
with asymptomatic elevations of aminotransferase levels at 
dosages of 4 g/day even in healthy adults, although the 
clinical significance of these findings is uncertain [11].
2. Tramadol
    Although the mode of action of tramadol is not com-
pletely understood, tramadol is a drug with a dual activity: 
one-third of its activity is due to an opioid-like mechanism 
and two-thirds are due to a mechanism similar to ami-
triptyline. It truly represents a multimodal drug to consider 
for pain management strategies [12]. Tramadol has proven 
effective  to  treat  osteoarthritis  (OA),  fibromyalgia  (FM), 
and neuropathic pain (NP). Because tramadol is an un-
scheduled drug, clinicians may not be aware of its opioid 
effect. However, it should be used with some caution in 
persons recovering from substance use disorders. While 
the degree of physical dependence appears to be relatively 
mild, patients have reported symptoms of psychic depend-
ence,  such  as  craving  tramadol  when  discontinuing  the 
drug [13]. Seizures have been reported with tramadol use 
i n  t h e  f o r m  o f  s e r o t o n i n  s y n d r o m e .  T h e r e f o r e ,  p a t i e n t s 
with a history of seizures and those taking a tricyclic or 
SSRI an ti d epr essan t, a m on oam in e o xi dase in hi bitor, an 
antipsychotic  drug,  or  other  opioids  may  be  at  an  in-
creased  risk  for  seizures  [14].  Daily  doses  of  tramadol 
should not exceed 400 mg. 
3. Opioid analgesics
    Most available opioids are μ-opioid receptor agonists 
or drugs with direct affinity for μ-opioid receptors. The 
pure agonists have no apparent ceiling effect for analgesia. 
The exception is meperidine (Demerol
Ⓡ) that is limited by 
an active metabolite nor-meperidine, which is associated 
with excitatory side effects with a risk of seizures. Meperi-
dine is not recommended for the treatment of chronic pain. 
Partial agonists with mixed agonist-antagonist action are 
generally not indicated for the treatment of chronic pain [15].
    There  is  growing  evidence  that  controlled-release 
opioid  analgesics  have  a  role  to  play  in  patients  with 
c h r o n i c  p a i n .  A  r e c e n t  m e t a - a n a l y s i s  o f  4 1  r a n d o m i z e d 
controlled trials involving 6,019 patients found that opioids 
were more effective than placebo for both the pain and 
functional outcomes of patients with nociceptive and neu-
ropathic pain [16]. The guidelines for the use of opioid an-
algesics for chronic noncancer pain have been established 
by the Canadian Pain Society [17], and the evidence sup-
ports the assertion that opioids are a reasonable and effi-
cacious treatment for people with chronic pain [18]. The 
average duration of the trials was only 5 weeks (range: 
1-16 weeks) and so there is a need for longer-term trials 
for  examining  the  efficacy  and  safety  parameters.  The 
recommended  front-line  agents  include  hydromorphone, 
morphine, and oxycodone used orally on a time-contingent 
basis.  Additional  options  include  the  fentanyl  patch  for 
cases  where  the  oral  route  is  not  a  reasonable  option 
(malabsorption, vomiting) or it has failed, and methadone H J  P a r k  a n d  D E  M o o n  /  P h a r m a c o t h e r a p y  o f  C h r o n i c  P a i n 101
Table 1. Oral and Transdermal Opioid Analgesic Equivalence
Drug Dose (mg) Duration (h)*
Morphine
Codeine
Hydrocodone
Oxycodone
Hydromorphone
Meperidine
Methadone
Fentanyl 
 (transdermal)
20–30
200
†
 30
‡ 
20
7.5
300
†
 20
§
1  μg/h transdermally≈morphine 
2 mg/24 h orally
2–4
3–4
4–6
3–4
3–4
2–4
4–8
48–72
*Duration of analgesia is dose dependent; the higher the dose, 
usually the longer the duration. 
†These high doses of codeine and
meperidine are not recommended clinically. 
‡Equianalgesic data not
available for hydrocodone. 
§In opioid-tolerant patients converted to
methadone, start with 10–25% of equianalgesic dose. Also, the 
half-life of methadone can vary widely from 12 to 190 h. 
if  t h e p r e vi o u s  c o n v e n t i o n a l  o p i o i d s  h a v e  f a il ed  [ 19 ] . A n 
evidence-based review evaluated the long-acting opioids 
and short-acting opioids for chronic noncancer pain [20]. 
The author concluded that there is insufficient evidence to 
suggest that 1 long-acting opioid is superior to the others. 
    A systematic review of 34 trials with 4,212 patients 
provided  information  on  the  adverse  events  related  to 
opioid use for treating noncancer pain [21]. Only 3 side ef-
f e c t s  ( n a u s e a ,  c o n s t i p a t i o n ,  a n d  s o m n o l e n c e )  o c c u r r e d  
significantly more frequently with opioids at 14%, 9%, and 
6%, respectively, than with placebo. A considerable pro-
portion of patients on opioids (22%) withdrew because of 
adverse events. Because most of the trials were short (＜ 
4 weeks) and the authors did not titrate the dose, the im-
plications of opioids for long-term use in clinical practice 
are less certain. Eisenberg et al. [22] also reported adverse 
events in their systematic review of opioids for NP. Opioid 
therapy compared to placebo resulted in higher reports of 
nausea (33% vs. 9%), constipation (33% vs. 10%), drowsi-
ness (29% vs. 12%), dizziness (21% vs. 6%), and vomiting 
(15% vs. 3%). More patients on opioids withdrew because 
of adverse effects (11% vs. 4%). Endocrinological abnor-
malities, such as hypogonadism and erectile dysfunction, 
may be associated with long term use of opioid therapy 
[23,24]. In women, opioid use has been associated with 
amenorrhea and decreased levels of sex hormones [25]. 
Opioid treatment may be associated with impaired neuro-
psychological performance regarding reaction times, psy-
chomotor speed, and working memory [26]. However, a re-
cent  systematic  review  concluded  that  stable  doses  of 
opioids did not impair driving performance [27]. 
  <General principles for the safe, effective use of opioids 
for managing chronic pain>
  1) Maximize the nonopioid analgesic strategies first (i.e., 
a ''delayed'' opioid approach).
  2) Inform subjects of the risks, including addiction, be-
fore initiating opioid therapy. 
  3) Facilitate the use of opioid agreements (contracts) for 
patients initiating opioid therapy or those with increasing 
doses of opioids. The key points include specifying the fre-
quency of obtaining medications, providing timely refills 
but no early replacement for lost or stolen prescriptions, 
providing  safe  storage,  no  sharing,  single-source  pre-
scribing, monitoring through urine screens, and adhering 
to monitored visits. 
  4) Schedule follow-up visits at 2- to 3-month intervals 
and perform periodic urine testing to confirm adherence. 
  5) Monitor the pain severity and pain-related functional 
i m p a i r m e n t  a t  f o l l o w - u p  v i s i t s  s i n c e  t h e  a n a l g e s i c  r e-
sponse may wane in some patients over time. 
  6) Avoid opioid dose escalations without first assessing 
the pain severity and the pain's interference with daily life.
  7) View opioid initiation as an empiric trial. Consider dis-
continuing opioids if they are not beneficial. 
  8) Consider opioid rotation according to the opioid con-
version ratio (Table 1) if tolerance to 1 opioid is suspected.
  9)  If  patient  is  a  high-risk  candidate  for  opioids 
(particularly those with a current or past SUD including al-
cohol or drugs), consider referral to a pain specialist.
4. Antidepressants
    Patients often discontinue this type of medication be-
cause side effects occur early, while the analgesia may 
take several weeks to occur. They must be informed they 
will become tolerant to the side effect and that analgesia 
needs some weeks to be evident. Patients must be in-
formed about the rationale for antidepressant therapy and 
that they are not being treated as though they are affected 
by psychological problems [28-30]. Antidepressants work 
at the spinal level by inhibiting the reuptake of the neural 
transmitters norepinephrine and serotonin, and so this po-
tentiates the inhibitory pathway in the dorsal horn of the 
spinal cord and at the ectopic sites in the peripheral nerves 
by blocking Na channels.102 Korean J Pain Vol. 23, No. 2, 2010
1) Tricyclic antidepressants (TCAs) and selective serotonin 
reuptake inhibitors (SSRIs): Tricyclic antidepressants have 
the longest track record of any antidepressant class for 
the treatment of multiple pain conditions. Typically, the 
doses of TCAs used in clinical trials for pain relief pain 
have been lower (e.g., 25-100 mg amitriptyline or equiv-
alent)  than  the  doses  that  are  typically  necessary  for 
treating  depression.  However,  some  experts  have  found 
that  titrating  TCAs  to  higher  doses  (with  an  option  of 
monitoring the serum levels) may further benefit a subset 
of patients. The advantages of TCAs include decades of 
clinical experience with T C As f or pain managemen t and 
their low cost. The disadvantages of TCAs are side effects 
(which may be less when prescribing the lower doses used 
for analgesia), including cardiovascular effects (e.g., hy-
pertension,  postural  hypotension,  arrhythmias),  falling 
down in older adult patients, and there is also potential le-
thality with an overdose.
    TCAs are superior to SSRIs for pain management. 
Admittedly,  the  statistical  comparisons  that  have  been 
done are not as conclusive as direct comparisons of anti-
depressan ts within the same trial. Another re view con-
cluded that SSRIs appeared to have a relatively weak effect 
for ameliorating chronic pain [31].
2)  Serotonin-norepinephrine  reuptake  inhibitors  (SNRIs): 
Duloxetine has been proven superior to placebo in three 
12-week  randomized,  placebo-controlled  trials  that  en-
rolled patients with pain due to diabetic peripheral neuro-
pathy [32-34]. Both the patients with and without depres-
sion were enrolled in the trials, although the path analysis 
estimated that more than 90% of the analgesic effect in 
the duloxetine-treated patients with diabetic neuropathy 
was attributable to a direct analgesic effect, with less than 
10% possibly explained by an antidepressant effect [35]. 
Duloxetine is also FDA approved for treating the chronic 
wi d es pr ea d pain o f FM [36 -38]. A  6 -w ee k t ria l o f e x-
tended-release venlafaxine in 224 patients with diabetic 
n e u r o p a t h y  f o u n d  v e n l a f a x i n e  s u p e r i o r  t o  p l a c e b o  [ 3 9 ] .  
Venlafaxine may also be useful in other painful conditions 
[40], but it does not have the FDA approved indication for 
pain treatment.
    A recent meta-analysis of 5 trials in depressed pa-
tients reported a very small and statistically insignificant 
analgesic effect for duloxetine [41]. Another meta-analysis 
o f 8  t ri a ls  t h a t  c o m p a r ed  d u l o x e t in e w i t h p a r o x e t in e  o r 
placebo for the painful physical symptoms of depression 
likewise concluded that there was insufficient evidence for 
an analgesic effect of duloxetine [42]. In all of these de-
pression trials, pain was examined as a secondary out-
come, and in all but 2 trials, an important proportion of 
patients had no pain. A subsequent placebo-controlled trial 
o f  d u l o x e t i n e  i n  p a t i e n t s  w i t h  d e p r e s s i o n  a n d  m o d e r -
ate-to-severe pain, but no organic pain diagnosis, found 
a significant benefit from duloxetine for both pain and de-
pression symptoms [43].
5. Anticonvulsants
    Anticonvulsants have been used for the management 
of pain since the 1960s and along with antidepressants, 
they  constitute  1  of  the  2  most  important  adjunctive 
classes of medications for pain management. The clinical 
impression is that they are useful for chronic NP, espe-
cially when the pain is described as lancinating or burning. 
Gabapentin and pregabalin have the strongest evidence for 
the treatment of pain. These 2 ''gabapentinoids'' act as 
neuromodulators by selectively binding to the α2-δ- sub-
unit protein of the calcium channels in various regions of 
the brain and the superficial dorsal horn of the spinal cord. 
T h e y  a l s o  h a v e  a  p e r i p h e r a l  a n a l g e s i c  a c t i o n  [ 4 4 - 4 6 ] .  
These actions result in inhibiting the release of excitatory 
neurotransmitters that are important in the production of 
pain.
    In the 14 chronic NP trials, 42% of the participants 
improved (i.e., pain relief of 50% or greater) on gabapentin 
vs. 19% on placebo. The withdrawal rates were 14% for ga-
bapentin vs. 10% for placebo. The FDA has approved pre-
gabalin for the treatment of NP associated with diabetic 
peripheral neuropathy and PHN and for the treatment of 
FM.
    Gabapentin and pregabalin should be considered as 
the first-line anticonvulsants for NP conditions other than 
trigeminal neuralgia. Gabapentin is now available in a ge-
neric formulation, making it less costly than pregabalin. 
Conversely, pregabalin has a simpler dosing schedule (twice 
daily compared to 3 to 4 times daily), possibly a simpler 
dose titration, and an additional FDA indication (FM).
    Other drugs worth trying are lamotrigine, clonazepam, 
a n d  v a l p r o a t e .  C a r b a m a z e p i n e  a n d  O x c a r b a z e p i n e  a r e  
considered the first effective drugs for trigeminal neural-
gia. Carbamazepine and Oxcarbazepine act peripherally on 
Na channels while the others work at spinal levels by dif-
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pre- and post-synaptic levels in the dorsal horn of the 
spinal cord [29,47].
6. Skeletal muscle relaxants
    Most skeletal muscle relaxants are FD A approved for 
either spasticity (baclofen, dantrolene, and tizanidine) or 
musculoskeletal  conditions  (carisoprodol,  chlorzoxazone, 
cyclobenzaprine, metaxalone, methocarbamol, and orphe-
nadrine) [48]. The mechanism of action for the latter cat-
egory of agents is unclear, but it may be related in part 
to  sedative  effects.  Cyclobenzaprine  is the best studied 
muscle relaxant in musculoskeletal disorders overall; in 21 
fair-quality trials, it has consistently proven superior to 
placebo for FM as well as for pain relief, muscle spasms, 
and  improving  the  functional  status  in  other  disorders. 
Muscle relaxants have a limited role for the treatment of 
chronic pain, ex cept f or cy clobenzaprine as 1 option f or 
treating FM.
7. T opical analgesics
    A potential advantage of topical agents is avoiding 
systemic side effects that are often associated with oral 
m e d i c a t i o n s .  T h e  d i s a d v a n t a g e s  a r e  t h a t  o n l y  l o c a l i z e d  
areas of pain can be effectively treated and that irritating 
skin reactions occur in a minority of patients. Topical an-
algesics probably have a circumscribed role in treating lo-
calized areas of mild to moderate neuropathic or osteo-
arthritic pain, either as an adjunct with other medications 
or as an alternative for patients who prefer not to ingest 
pills. Several topical analgesics (lidocaine, capsaicin, and 
salicylate) have been studied in multiple trials. A 5% lido-
caine patch has an FDA indication for PHN. It is applied 
for 12 h daily. The systemic levels absorbed are very low 
due to lidocaine working via a local mechanism.
    Capsaicin is an alkaloid deriv ed from chili peppers; re-
peated application is thought to lead to depletion of sub-
stance P from the primary afferent neurons [49]. The main 
disadvantage of capsaicin is the initial burning sensation, 
which may persist for days. Capsaicin must be applied 3-4 
times per day over the entire painful area for up to 6-8 
weeks before optimal pain relief can be achieved. Capsaicin 
0 . 0 7 5 %  i s  u s e d  f o r  n e u r o p a t h i c  p a i n ,  a n d  C a p s a i c i n  
0 . 0 2 5 %  i s  u s e d  f o r  a r t h r i t i c  p a i n .  A  n e w  p o t e n t  ( 8 % )  
strength patch has shown promising results. It needs to 
be applied in the hospital after patient sedation or after 
the skin has been anaesthetized because it is strongly irri-
tating, but a 1 h application can result in analgesia that 
lasts for several weeks. Mason et al. [50] recently reviewed 
the clinical trial evidence for capsaicin, including 6 trials 
for NP and  3  trials for musculoskeletal  conditions.  They 
found that 57% of the patients with NP achieved at least 
50% pain relief with capsaicin, compared to 42% of the 
patients on placebo; for patients with musculoskeletal con-
ditions, the response rates were 38% vs. 25%, respectively 
[50]. Around one third of the patients experienced local 
adverse events with capsaicin.
    T opical salicylate has proven superior to placebo for 
treating chronic pain [51]. However, the larger, more rig-
orous trials have tended to be negative. A recent study 
suggests topical ibuprofen may also be beneficial for knee 
OA  [52].
TREATMENT  PLAN
    First of all, it is important that physicians understand 
the multifactorial nature of chronic pain and the physio-
logical differences between nociceptive pain and neuro-
pathic pain. They had better do a multi-mechanistic ap-
p r o a c h  w i t h  t a k i n g  i n t o  a c c o u n t  s t e p w i s e  s e l e c t i o n  o f  
pharmacotherapy  (Fig.  1)  [15].  A  multi-mechanistic  ap-
proach means combining 2 substances from different drug 
classes,  or  administering  an  analgesic  with  2  different 
mechanisms  of action.  In some  circumstances, a single 
compound  capable  of  addressing  both  nociceptive  and 
neuropathic pain is desirable [2].
    In addition, physicians have to modify treatment for 
p e d i a t r i c ,  g e r i a t r i c ,  h e p a t i c ,  a n d  r e n a l  f a i l u r e  p a t i e n t s .  
Generally, all drugs should be administered cautiously for 
these cases. The dose should be low and titrated slowly 
to avoid toxicity. It has been suggested that up to 40% 
of children lack the enzyme to metabolize codeine to mor-
p h i n e  [ 5 3 ] .  I n  t h e s e  c i r c u m s t a n c e s ,  a  m e d i c a t i o n  s u b-
stitution should be attempted. Meperidine use is not rec-
ommended in children because of the side effects encoun-
tered  due  to  the  main  metabolite,  normeperidine  [54]. 
Although NSAIDs are a good option, they should be avoided 
in children younger than 6 months of age and children with 
NSAID or aspirin allergy, hypovolemia or dehydration, renal 
or hepatic failure, peptic ulcer disease, or coagulopathies 
[54]. Children on anticoagulants, steroids, and nephrotoxic 
agents should not receive NSAIDs. 
    The  considerations  for  geriatric  patients  are  as 104 Korean J Pain Vol. 23, No. 2, 2010
Fig. 1. Treatment algorithm 
for pharmacotherapy of chro-
nic noncancer pain. In gene-
ral, if one agent in a class of 
medications does not pro-
vide adequate analgesia or 
causes limiting side effects, 
it is worth pursuing serial 
trials of 1 or 2 others from 
the class. Topicals may be 
introduced at any point as a 
sole agent or in combination.
f ollows. First, consider the risk/benefit ratio of NSAIDs. 
Second, when using NSAIDs in persons 60 years and older, 
a proton pump inhibitor should be added as prophylaxis 
against GI bleeding in those patien ts with GI sym ptoms 
(dyspepsia or gastroesophageal reflux) or those patients 
who are on antiplatelet agents (e.g., aspirin, clopidogrel) 
o r  c o r t i c o s t e r o i d s  [ 5 5 ] .  T h i r d ,  a m i t r i p t y l i n e  a n d  c y c l o -
benzaprine should probably be avoided due to their highly 
anticholingergic  properties.  Fourth,  opioids  should  be 
started at low doses and titrated slowly, and special atten-
tion should be paid to preventing constipation. 
    Aspirin should be avoided for patients with end-stage 
renal  disease,  and  dosage  adjustments  should  be  made 
when ASA is used for long-term therapy in a hepatically 
compromised patient [56]. Acetaminophen is used with an 
increased dose interval in hepatic and renal failure patients 
[57,58]. Tramadol, hydromorphone, and morphine are used 
very cautiously at a reduced dose in the presence of kidney H J  P a r k  a n d  D E  M o o n  /  P h a r m a c o t h e r a p y  o f  C h r o n i c  P a i n 105
Table 2. Comparison of Neuropathic Pain Treatment Guidelines, Excluding Trigeminal Neuralgia*
Medication class NeuPSIG guidelines CPS guidelines EFNS guidelines
Tricyclic antidepressants
Calcium channel α2-δ ligands 
 (gabapentin and pregabalin)
SNRIs (duloxetine and venlafaxine)
Topical lidocaine
Opioid analgesics
Tramadol
First line
First line
First line
First line for localized 
 peripheral NP
Second line except in 
 selected circumstances
†
Second line except in 
 selected circumstances
†
First line
First line
Second line
Second line for localized 
 peripheral NP
Third line
Third line
First line for PPN, PHN, and CP
First line for PPN, PHN, and CP
Second line for PPN
First line for PHN if small area of 
 pain/allodynia
Second-third line for PPN, PHN, and CP
Second-third line for PPN and PHN
NeuPSIG: Neuropathic Pain Special Interest Group, CPS: Canadian Pain Society, EFNS: European Federation of Neurological Societies,
PPN: painful polyneuropathy, PHN: postherpetic neuralgia, CP: central pain, SNRIs: serotonin and norepinephrine reuptake inhibitors, NP:
neuropathic pain. *Only medications considered first or second line in 1 of the guidelines are presented. 
†Opioid analgesics and tramadol
were considered first-line options in the following circumstances: for the treatment of acute NP, episodic exacerbations of severe NP, 
neuropathic cancer pain, and during titration of a first-line medication in patients with substantial pain. 
and liver abnormalities [56,59,60]. Few studies are avail-
able to examine the safety of morphine in conjunction with 
l i v e r  f a i l u r e ;  a n y  h e p a t i c  r e c o m m e n d a t i o n s  a r e  n o t  
available.  Codeine,  dihydrocodeine,  and  dextropropoxy-
phene are not recommended for use in the presence of re-
nal failure [59,60]. Fentanyl is an ideal choice for patients 
with renal failure because of the lack of active metabolites, 
yet it is likely that fentanyl clearance is delayed because 
of hepatic failure, and this is because fentanyl is subject 
to a high hepatic extraction ratio [61]. 
    Three evidence-based consensus guidelines for the 
pharmacologic treatment of neuropathic pain have recently 
been  updated:  (1)  the  International  Association  for  the 
S t u d y  o f  P a i n  N e u r o p a t h i c  P a i n  S p e c i a l  I n t e r e s t  G r o u p  
(NeuPSIG) guidelines, (2) the Canadian Pain Society (CPS) 
guidelines, and (3) the European Federation of Neurological 
Societies (EFNS) guidelines (Table 2) [62]. These guidelines 
all  recommend  TCAs,  gabapentin,  and  pregabalin  as 
first-line treatment options for patients with neuropathic 
p a in  (e x c l u d i ng t r ige m i n a l n e u r a lgi a ).  T h e y  a ls o r ec o m-
mend reserving opioid analgesics and tramadol as second- 
or third-line options in most cases, despite the evidence 
of their efficacy for neuropathic pain. In 2 of the guide-
l i n e s ,  t o p i c a l  l i d o c a i n e  i s  r e c o m m e n d e d  a s  a  f i r s t - l i n e  
treatment for patients with localized peripheral neuropathic 
pain (particularly in patients with postherpetic neuralgia 
and allodynia), whereas the other guideline considers top-
i c a l  l i d o c a i n e  a  s e c o n d - l i n e  t r e a t m e n t .  T h e  N e u P S I G  
guidelines recommend duloxetine and venlafaxine as first- 
line treatment options, but the Canadian Pain Society and 
EFNS guidelines recommend these SNRIs as second-line 
options for patients with painful polyneuropathies.
    Even if a correct treatment is started, there are some 
concerns to keep in mind. Insufficient dosage is another 
possible explanation for treatment failure. It may be diffi-
cult to maintain the balance between adequate pain relief 
and acceptable tolerability, as well as side effects, of the 
pharmacotherapy. This may be explained by the hypoth-
esis of the Vicious Circle, which is particularly applicable 
to classical opioids, but also plays a role in combination 
therapy (Fig. 2) [2]. Informing and supplying the patient 
with information is mandatory not only at the beginning, 
but also when the effective drug combination and dosages 
have been  found. The patient  should be  convinced that 
chronic  pain  needs  chronic  therapy.  Patients  frequently 
stop therapy due to fear of addiction and toxicity. Also, 
the  cost  of  the  therapy  is  another  reason  to  stop  the 
treatment. Finally, it is necessary that physicians individu-
alize the pharmacotherapy of each patient. 
SUMMARY
    A number of medications have proven to be effective 
in chronic pain disorders and their use individually or in 
com bination sh o u ld im pr o v e the m an agemen t of chr onic 
pain. Especially for neuropathic pain, the medications rec-106 Korean J Pain Vol. 23, No. 2, 2010
Fig. 2. The Vicious Circle 
showing interaction of influ-
encing factors.
ommended as first-line treatments include TCAs, SNRIs, 
calcium channel α2-δ ligands, and lidocaine patch. Opioid 
analgesics and tramadol are recommended as second-line 
treatments that can be considered for first-line use in se-
lected clinical circumstances. A thorough understanding of 
pain mechanisms and good communication between physi-
cians and patients are required to improve patient out-
comes. Avoiding ineffective treatments and maximizing the 
treatments that have been proven beneficial in clinical tri-
als (i.e., evidence-based treatments) are likely to produce 
better  outcomes  than  have  often  been  experienced  by 
clinicians and patients in the management of chronic pain. 
Additionally, identifying and co-managing pain that is co-
morbid with psychiatric disorders have promise for improv-
ing both the physical and psychological outcomes. Further-
more, the m ulti-modality treatmen t of chronic pain in-
c o r p o r a t e s  n o t  o n l y  t h i s  a p p r o a c h  t o  p h a r m a c o l o g i c a l  
treatment, but also non-pharmacological strategies such 
as interventional pain management, physiotherapy, psy-
chotherapy, and pain rehabilitation.
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